Rafferty Asset Management
CGEM icon

Rafferty Asset Management’s Cullinan Oncology CGEM Stock Holding History

Rafferty Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
66,092
-3,393
-5% -$50.4K ﹤0.01% 752
2026
Q1 		$987K Buy
69,485
+7,814
+13% +$100K ﹤0.01% 777
2025
Q4 		$638K Buy
61,671
+20,942
+51% +$189K ﹤0.01% 874
2025
Q3 		$242K Buy
40,729
+1,503
+4% +$11K ﹤0.01% 1038
2025
Q2 		$295K Sell
39,226
-15,716
-29% -$126K ﹤0.01% 984
2025
Q1 		$416K Sell
54,942
-34,716
-39% -$333K ﹤0.01% 906
2024
Q4 		$1.09M Sell
89,658
-25,012
-22% -$360K ﹤0.01% 774
2024
Q3 		$1.92M Buy
114,670
+10,019
+10% +$178K 0.01% 646
2024
Q2 		$1.83M Buy
104,651
+7,596
+8% +$162K 0.01% 672
2024
Q1 		$1.65M Buy
+97,055
New +$1.5M 0.01% 733
2022
Q2 		– Sell
-55,152
Closed -$577K – 1151
2022
Q1 		$577K Sell
55,152
-15,987
-22% -$216K ﹤0.01% 928
2021
Q4 		$1.1M Buy
+71,139
New +$1.42M 0.01% 827

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Rafferty Asset Management's CGEM Position: Q2 2026 in Review

Rafferty Asset Management reduced its Cullinan Oncology (CGEM) stake by 4.9% in Q2 2026, selling an estimated $50.4K and leaving 66,092 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #752.

Rafferty Asset Management first reported a position in CGEM in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.92M in Q3 2024. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Rafferty Asset Management held 66,092 shares of Cullinan Oncology worth $1.2M as of Q2 2026.
  • Rafferty Asset Management sold 3,393 Cullinan Oncology shares in Q2 2026, an estimated $50.4K.
  • Cullinan Oncology made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #752 holding.
  • Rafferty Asset Management first reported a position in Cullinan Oncology in Q4 2021 and has held it in 12 quarters since.
  • Rafferty Asset Management's Cullinan Oncology position peaked at $1.92M in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.